← Back to Clinical Trials
Recruiting NCT07176273

NCT07176273 Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07176273
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition Posttraumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 302 participants
Start Date 2025-12-12
Primary Completion 2028-05-22

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Modular Cognitive Processing TherapyModular Prolonged Exposure TherapyStep Down Treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 302 participants in total. It began in 2025-12-12 with a primary completion date of 2028-05-22.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

By doing this research project, the investigators hope to learn which strategies work best to help veterans who are not benefiting from their first PTSD treatment or not completing between-session homework assignments regularly that might improve treatment response. The investigators also want to learn how best to match the right type and amount of treatment to each individual veteran. By conducting this research project, they hope to: * See if trying a different treatment strategy for veterans not responding to their first PTSD treatment would be more helpful * See if sending text message prompts between sessions encourages more completion of between-session homework

Eligibility Criteria

Inclusion Criteria: 1. Veterans eligible for PE and CPT at the participating PTSD treatment-providing clinic who are 2. At least 18 years or older 3. Score ≥ 31 on the PCL-5 secondary to a Criterion A traumatic event 4. Own a mobile device that can be used for the therapy companion mobile app (Prolonged Exposure (PE) coach or Cognitive Processing Therapy (CPT) coach). Exclusion Criteria: 1. Acute suicide risk requiring clinical intervention 2. Need for detoxification 3. Unmanaged psychosis or bipolar disorder 4. Severe cognitive impairment that makes it unlikely that participants can adhere to the study regimen (as evidenced by confusion, inability to track discussion or answer questions, or other clear and significant indicators of cognitive impairment) 5. Current or past 12-month engagement in PE or CPT.

Contact & Investigator

Central Contact

Stefanie LoSavio, PhD

✉ losavio@uthscsa.edu

📞 210-562-6700

Principal Investigator

Stefanie LoSavio, PhD

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT07176273 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Posttraumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07176273 currently recruiting?

Yes, NCT07176273 is actively recruiting participants. Contact the research team at losavio@uthscsa.edu for enrollment information.

Where is the NCT07176273 trial being conducted?

This trial is being conducted at Augusta, United States, Ann Arbor, United States, Battle Creek, United States, Salt Lake City, United States.

Who is sponsoring the NCT07176273 clinical trial?

NCT07176273 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Stefanie LoSavio, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 302 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology